Post Profile

Summit therapeutics soars on Sarepta deal

Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics.        
read more


Related Posts

Aviragen Therapeutics Licenses Georgia State Technology to Develop Antiviral Therapies

Health : Newswise Medical News

The Georgia State University Research Foundation (GSURF) has entered into a licensing and sponsored research agreement with Aviragen Therapeutics, Inc., a Georgia-based pharmaceutical company developing the next generation of antivi...

Sarepta Therapeutics Inc (SRPT): Sad Trombone?

Business & Finance / Investing : Insider Monkey

The words of the great big-band leader Duke Ellington came to mind after hearing the first quarter results from Sarepta Therapeutics Inc (NASDAQ:SRPT) : “It don’t mean a thing.”  Here are the highlights from those results — and why ...

Sarepta Therapeutics Inc (SRPT): Why This Stock’s Shares Fell

Business & Finance / Investing : Insider Monkey

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis. What: Shares of Sarepta Therapeutics Inc (NASDAQ:SR...

Stony Brook Enters Licensing Deal to Bring Anti-Cancer Technology to Market

Health : Newswise Medical News

Stony Brook University has entered into a licensing agreement with a startup company, CadheRx Therapeutics, to develop and market an anti-cancer technology discovered by Sabine Brouxhon, MD, Clinical Associate Professor in the Depar...

Summit and Sarepta to collaborate on muscular dystrophy drug

Health : Reuters: Health

(Reuters) - Drugmaker Sarepta Therapeutics Inc has entered into an exclusive license agreement with Britain's Summit Therapeutics Plc to develop drugs to treat Duchenne muscular dystrophy (DMD), the companies said on Tuesday.


Copyright © 2016 Regator, LLC